ES2263405T1 - Produccion de proteinas capsidas y particulas tipo virus de papilomavirus humano. - Google Patents
Produccion de proteinas capsidas y particulas tipo virus de papilomavirus humano.Info
- Publication number
- ES2263405T1 ES2263405T1 ES05075369T ES05075369T ES2263405T1 ES 2263405 T1 ES2263405 T1 ES 2263405T1 ES 05075369 T ES05075369 T ES 05075369T ES 05075369 T ES05075369 T ES 05075369T ES 2263405 T1 ES2263405 T1 ES 2263405T1
- Authority
- ES
- Spain
- Prior art keywords
- virus
- particle
- type
- hpv
- capsomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract 12
- 108090000565 Capsid Proteins Proteins 0.000 title claims abstract 7
- 239000002245 particle Substances 0.000 claims abstract 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract 8
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract 6
- 108091026890 Coding region Proteins 0.000 claims abstract 5
- 241000701806 Human papillomavirus Species 0.000 claims abstract 5
- 241001631646 Papillomaviridae Species 0.000 claims abstract 3
- 230000001900 immune effect Effects 0.000 claims abstract 2
- 230000000877 morphologic effect Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 7
- 241000701447 unidentified baculovirus Species 0.000 claims 6
- 210000004392 genitalia Anatomy 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 208000003154 papilloma Diseases 0.000 claims 4
- 241000238631 Hexapoda Species 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000006472 autoimmune response Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940031348 multivalent vaccine Drugs 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Una partícula o capsómero tipo virus del papiloma virus humano recombinante purificada que comprende una proteína cápsida del papiloma virus L1 humano tipo genital expresada a partir de una secuencia codificadora de proteína L1, la cual produce una proteína o complejo de proteínas que posee características inmunológicas y morfológicas similares a aquéllas de los papilomavirus naturales, en la que dicha partícula o capsómero es capaz de reconocer anticuerpos en sueros humanos de personas que se conoce están infectadas con virus homólogos.
Claims (17)
1. Una partícula o capsómero tipo virus del
papiloma virus humano recombinante purificada que comprende una
proteína cápsida del papiloma virus L1 humano tipo genital expresada
a partir de una secuencia codificadora de proteína L1, la cual
produce una proteína o complejo de proteínas que posee
características inmunológicas y morfológicas similares a aquéllas de
los papilomavirus naturales, en la que dicha partícula o capsómero
es capaz de reconocer anticuerpos en sueros humanos de personas que
se conoce están infectadas con virus homólogos.
2. Una partícula tipo virus según la
reivindicación 1 la cual tiene un diámetro coherente con el diámetro
de los viriones aislados del papilomavirus.
3. Una partícula o capsómero tipo virus según
las reivindicaciones 1 ó 2 en la que dicha secuencia codificadora de
la proteína L1 es expresada en una célula usando un sistema de
expresión de baculovirus.
4. Una partícula o capsómero tipo virus según
una cualquiera de las reivindicaciones de la 1 a la 3 en la que el
papiloma virus humano de tipo genital es un papiloma humano de tipo
cáncer genital.
5. Una partícula o capsómero de tipo virus según
la reivindicación 4 donde el papiloma humano es uno cualquiera de
HPV-16, HPV-18,
HPV-31, HPV-33 y
HPV-35.
6. Una partícula o capsómero tipo virus según la
reivindicación 5 donde el papiloma humano es
HPV-18.
7. Una partícula o capsómero tipo virus según
cualquiera de las reivindicaciones anteriores consistente en una
proteína cápsida L1.
8. Una partícula o capsómero tipo virus de
cualquiera de las reivindicaciones anteriores para uso como una
vacuna.
9. Una vacuna que consta de una partícula o
capsómero tipo virus de cualquiera de las reivindicaciones
anteriores.
10. Una vacuna según la reivindicación 9 la cual
es una vacuna multivalente que consta de una partícula o capsómero
tipo virus de diferentes virus de papiloma humano.
11. Una vacuna según las reivindicaciones 9 ó 10
que comprende adicionalmente un adyuvante.
12. El uso de una partícula o capsómero tipo
virus según una cualquiera de las reivindicaciones de la 1 a la 7 en
la elaboración de una vacuna para conferir sea una protección inmune
contra el virus del papiloma humano o, si el paciente esta ya
infectado, para aumentar la respuesta autoinmune del paciente.
13. Un método de producción de una partícula o
capsómero tipo virus según la reivindicación 1 el método que consta
de una célula transfectadora con un vector de expresión recombinante
que contiene una secuencia codificadora de proteína cápsida HPV L1
de tipo genital en condiciones que faciliten la expresión de dicha
proteína cápsida, de ese modo produciendo dichas partículas o
capsómeros de tipo virus.
14. Un método según la reivindicación 13 donde
el vector de expresión recombinante es un sistema de expresión de
baculovirus.
15. Un método según la reivindicación 14 donde
la célula es una célula de insecto.
16. Un método según la reivindicación 15, donde
dicha transfección es llevada a cabo por infección.
17. Un método según cualquiera de las
reivindicaciones de la 13 a la 16, el método que comprende:
- clonar una secuencia codificadora de proteína cápsida HPV L1 de tipo genital en un vector de transferencia de baculovirus;
- contransfectar células de insectos con dicho vector de transferencia de baculovirus y ADN genómico del virus de polihedrosis nuclear Autographa californica;
- recuperar baculovirus recombinantes; e
- infectar células de insectos con dicho baculovirus recombinante en condiciones que faciliten la expresión de dicha proteína, produciendo de ese modo partículas tipo virus.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28517 | 1993-03-09 | ||
| US08/028,517 US8062642B1 (en) | 1993-03-09 | 1993-03-09 | Production of papillomavirus capsid protein and virus-like particles |
| US20730994A | 1994-03-07 | 1994-03-07 | |
| US207309 | 1994-03-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2263405T1 true ES2263405T1 (es) | 2006-12-16 |
| ES2263405T3 ES2263405T3 (es) | 2011-04-20 |
Family
ID=26703787
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05075889T Expired - Lifetime ES2263406T3 (es) | 1993-03-09 | 1994-03-08 | Producción de la proteína de capside l1 del papilomavirus humano hpv-11 y partículas de tipo virus. |
| ES94912186T Expired - Lifetime ES2242955T4 (es) | 1993-03-09 | 1994-03-08 | Produccion de la proteina de la capside del virus del papiloma humano y particulas de tipo viral. |
| ES05075369T Expired - Lifetime ES2263405T3 (es) | 1993-03-09 | 1994-03-08 | Producción de proteína de capside del papilomavirus humano y partículas de tipo virus. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05075889T Expired - Lifetime ES2263406T3 (es) | 1993-03-09 | 1994-03-08 | Producción de la proteína de capside l1 del papilomavirus humano hpv-11 y partículas de tipo virus. |
| ES94912186T Expired - Lifetime ES2242955T4 (es) | 1993-03-09 | 1994-03-08 | Produccion de la proteina de la capside del virus del papiloma humano y particulas de tipo viral. |
Country Status (14)
| Country | Link |
|---|---|
| EP (3) | EP0688227B1 (es) |
| JP (4) | JPH08507685A (es) |
| AT (3) | ATE492289T1 (es) |
| AU (3) | AU688759C (es) |
| CA (1) | CA2157932C (es) |
| DE (9) | DE122011100018I1 (es) |
| DK (2) | DK1618888T3 (es) |
| ES (3) | ES2263406T3 (es) |
| FR (1) | FR11C0022I2 (es) |
| HK (2) | HK1082196A1 (es) |
| LU (3) | LU91313I2 (es) |
| NL (3) | NL300265I2 (es) |
| PT (2) | PT688227E (es) |
| WO (1) | WO1994020137A1 (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1359156T3 (da) | 1991-07-19 | 2007-04-10 | Univ Queensland | Vaccine mod humanpapillomavirus |
| US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| AUPM358894A0 (en) * | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
| DE4415743C2 (de) * | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
| AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
| AU2003235191B2 (en) * | 1994-10-07 | 2006-09-21 | Loyola University Of Chicago | Papilloma virus-like particles, fusion proteins as well as processes for their production |
| ATE325875T1 (de) | 1994-10-07 | 2006-06-15 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
| AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| JP3958360B2 (ja) * | 1995-02-24 | 2007-08-15 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
| IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
| US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
| US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| ATE258222T1 (de) * | 1995-11-15 | 2004-02-15 | Merck & Co Inc | Synthetische hpv11 virusartige partikel |
| DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| US6908615B1 (en) | 1996-03-18 | 2005-06-21 | Merck & Co., Inc. | DNA encoding human papilloma virus type 18 |
| FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| JP2001506485A (ja) * | 1996-10-04 | 2001-05-22 | メルク エンド カンパニー インコーポレーテッド | 合成ｈｐｖ１６ウイルス様粒子 |
| WO1998025646A1 (en) * | 1996-12-09 | 1998-06-18 | Merck & Co., Inc. | Synthetic hpv16 virus-like particles |
| US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
| DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| JP4746819B2 (ja) * | 2000-09-18 | 2011-08-10 | メディミューン，エルエルシー | ワクチンの免疫原性を測定する試験管内検定 |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| EP1425423B1 (en) | 2001-08-13 | 2010-06-23 | University of Rochester | Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| CA2531773A1 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
| WO2006113209A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| WO2006065166A1 (fr) * | 2005-07-26 | 2006-06-22 | Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' | Composition de traitement et de prevention de l'infection de l'humain par le papillomavirus sur la base de la proteine l1 et des peptides de la proteine e7 |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| WO2008082719A2 (en) | 2006-08-30 | 2008-07-10 | University Of Rochester | Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors |
| PT2068918E (pt) | 2006-09-26 | 2012-08-06 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20100055166A1 (en) | 2007-03-02 | 2010-03-04 | Gerald Hermann Voss | Novel method and compositions |
| US9364529B2 (en) | 2007-04-29 | 2016-06-14 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of human papillomavirus type 18 |
| CN101293918B (zh) | 2007-04-29 | 2013-03-27 | 北京万泰生物药业股份有限公司 | 截短的人乳头瘤病毒16型l1蛋白 |
| DK2154149T3 (da) * | 2007-05-29 | 2019-10-14 | Univ Xiamen | En trunkeret l1-protein af human papillomavirus 6 |
| EP2910566B1 (en) | 2007-05-29 | 2016-07-13 | Xiamen University | A truncated L1 protein of human papillomavirus 11 |
| WO2009092113A2 (en) * | 2008-01-19 | 2009-07-23 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| AR071910A1 (es) | 2008-05-26 | 2010-07-21 | Cadila Healthcare Ltd | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
| WO2010112533A1 (en) * | 2009-04-03 | 2010-10-07 | Deutsches Krebsforschungszentrum | Enhanced production of papillomavirus-like particles with a modified baculovirus expression system |
| EP2437753B1 (en) | 2009-06-05 | 2016-08-31 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| EP2556377B1 (en) | 2010-04-08 | 2017-07-12 | University of Pittsburgh - Of the Commonwealth System of Higher Education | B-cell antigen presenting cell assay |
| CA2832307A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| DK2811981T3 (da) | 2012-02-07 | 2019-06-11 | Infectious Disease Res Inst | Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf |
| CA2866582A1 (en) | 2012-03-18 | 2013-09-26 | Brigitte Desiree Alberte Colau | Method of vaccination against human papillomavirus |
| BR112014028476A2 (pt) | 2012-05-16 | 2017-08-01 | Immune Design Corp | fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito |
| WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| WO2014172637A1 (en) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| KR102411781B1 (ko) | 2013-12-31 | 2022-06-22 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 단일 바이알 백신 제형 |
| JP7005504B2 (ja) | 2016-02-22 | 2022-01-21 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 生体分子の固定化方法 |
| CN109310773B (zh) | 2016-05-16 | 2022-04-26 | 传染病研究所 | 含有tlr激动剂的配制品和使用方法 |
| AU2017268175B2 (en) | 2016-05-16 | 2023-02-23 | Access To Advanced Health Institute | PEGylated liposomes and methods of use |
| MX2021010105A (es) | 2016-06-01 | 2022-06-16 | Infectious Disease Res Inst | Particulas de nanoalumbre que contienen un agente de dimensionamiento. |
| JP2020524143A (ja) | 2017-06-15 | 2020-08-13 | インフェクシャス ディズィーズ リサーチ インスティチュート | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
| EP3678695A1 (en) | 2017-09-08 | 2020-07-15 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
| CA3141577A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
| AU2021337493A1 (en) | 2020-09-04 | 2023-05-18 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
| EP4291231A1 (en) | 2021-02-11 | 2023-12-20 | GlaxoSmithKline Biologicals S.A. | Hpv vaccine manufacture |
| WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956288A (en) * | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| NZ232913A (en) * | 1989-03-15 | 1992-08-26 | Gist Brocades Nv | Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations |
| DK1359156T3 (da) * | 1991-07-19 | 2007-04-10 | Univ Queensland | Vaccine mod humanpapillomavirus |
-
1994
- 1994-03-08 EP EP94912186A patent/EP0688227B1/en not_active Expired - Lifetime
- 1994-03-08 DK DK05075369.8T patent/DK1618888T3/da active
- 1994-03-08 DE DE201112100018 patent/DE122011100018I1/de active Pending
- 1994-03-08 DK DK94912186T patent/DK0688227T3/da active
- 1994-03-08 DE DE69435332T patent/DE69435332D1/de not_active Expired - Lifetime
- 1994-03-08 DE DE05075369T patent/DE05075369T1/de active Pending
- 1994-03-08 JP JP6520236A patent/JPH08507685A/ja not_active Withdrawn
- 1994-03-08 PT PT94912186T patent/PT688227E/pt unknown
- 1994-03-08 CA CA2157932A patent/CA2157932C/en not_active Expired - Lifetime
- 1994-03-08 WO PCT/US1994/002443 patent/WO1994020137A1/en active IP Right Grant
- 1994-03-08 DE DE122007000090C patent/DE122007000090I1/de active Pending
- 1994-03-08 DE DE122007000089C patent/DE122007000089I1/de active Pending
- 1994-03-08 AT AT05075889T patent/ATE492289T1/de not_active IP Right Cessation
- 1994-03-08 DE DE69435331T patent/DE69435331D1/de not_active Expired - Lifetime
- 1994-03-08 ES ES05075889T patent/ES2263406T3/es not_active Expired - Lifetime
- 1994-03-08 AT AT05075369T patent/ATE494005T1/de active
- 1994-03-08 DE DE05075889T patent/DE05075889T1/de active Pending
- 1994-03-08 PT PT05075369T patent/PT1618888E/pt unknown
- 1994-03-08 EP EP05075369A patent/EP1618888B1/en not_active Expired - Lifetime
- 1994-03-08 AU AU64436/94A patent/AU688759C/en not_active Expired
- 1994-03-08 DE DE1994634383 patent/DE122007000014I1/de active Pending
- 1994-03-08 DE DE69434383T patent/DE69434383T2/de not_active Expired - Lifetime
- 1994-03-08 EP EP05075889A patent/EP1588713B1/en not_active Expired - Lifetime
- 1994-03-08 ES ES94912186T patent/ES2242955T4/es not_active Expired - Lifetime
- 1994-03-08 AT AT94912186T patent/ATE296111T1/de active
- 1994-03-08 ES ES05075369T patent/ES2263405T3/es not_active Expired - Lifetime
-
2006
- 2006-03-14 HK HK06103227.3A patent/HK1082196A1/xx not_active IP Right Cessation
- 2006-03-28 HK HK06103842.8A patent/HK1082206A1/xx not_active IP Right Cessation
- 2006-10-11 JP JP2006277056A patent/JP4486075B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-21 LU LU91313C patent/LU91313I2/fr unknown
- 2007-02-21 NL NL300265C patent/NL300265I2/nl unknown
- 2007-03-07 AU AU2007201005A patent/AU2007201005B2/en not_active Expired
- 2007-03-07 AU AU2007201006A patent/AU2007201006B2/en not_active Expired
- 2007-12-14 NL NL300310C patent/NL300310I1/nl unknown
- 2007-12-14 LU LU91391C patent/LU91391I2/fr unknown
- 2007-12-14 LU LU91392C patent/LU91392I2/fr unknown
- 2007-12-14 NL NL300309C patent/NL300309I2/nl unknown
-
2010
- 2010-02-05 JP JP2010023691A patent/JP5386392B2/ja not_active Expired - Lifetime
- 2010-02-05 JP JP2010023690A patent/JP5306251B2/ja not_active Expired - Lifetime
-
2011
- 2011-07-04 FR FR11C0022C patent/FR11C0022I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2263405T1 (es) | Produccion de proteinas capsidas y particulas tipo virus de papilomavirus humano. | |
| Suzich et al. | Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. | |
| DE69233687D1 (de) | Impfstoff gegen Humanes Papillomavirus (Typ 18) | |
| CN101518647A (zh) | 人乳头瘤病毒预防性疫苗、构建方法及应用 | |
| WO1999061052A3 (en) | Oral immunization with papillomavirus virus-like particles | |
| AU2003232951B2 (en) | Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles. | |
| SK4222002A3 (en) | Vaccine | |
| García-Carrancá | Vaccines against human papillomavirus and perspectives for the prevention and control of cervical cancer | |
| Sapp et al. | Synthesis, properties and applications of papillomavirus-like particles | |
| Sitarz | HPV vaccines | |
| Stanley | Prophylactic HPV vaccines: preclinical and proof of principle studies | |
| Ghim et al. | Comparison of PV conformational epitopes expressed by L1 proteins in mammalian (cos) and insect (Sf9) cells | |
| Malboeuf | Human papillomavirus-like particle-mediated gene delivery in vitro and in vivo: Implications for development of DNA/particle-based immunogens | |
| García-Carrancá | Vacunas contra virus del papiloma humano y perspectivas para la prevención y el control del cáncer cervicouterino |